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 فعالية عالية لدواء برازيكوانتيل يف أطفال مصابني بطفيل البلهارسية
الدموية يف والية ترابا بنيجرييا
دراسة متابعة
روبرت هم�شو، بنجا واما، هيمن اأقري، جون يونقا، أليزابيث اأموتا، �شانتايا كيال
abstract: Objectives: This study aimed to assess the efficacy of praziquantel in reducing urinary schistosomiasis 
prevalence, parasite burden and morbidity rates among a previously reported sample of Schistosoma haematobium-
infected children. In addition, predisposing factors for reinfection one year post-treatment were also determined. 
Methods: This prospective follow-up study was conducted between March 2014 and February 2015 among 675 
previously reported children with urinary schistosomiasis in the Murbai and Surbai communities of Ardo Kola, 
Taraba State, Nigeria. A single dose of 40 mg/kg of praziquantel was administered to each infected child, with a 
second dose administered one month later if necessary. The number of S. haematobium eggs in urine samples was 
calculated at baseline and post-treatment. Results: At four weeks post-treatment, the overall cure rate was 98.1%. 
Among children with low and heavy parasite burdens at baseline, egg reduction rates (ERRs) were 100% and 96.5%, 
respectively. The vast majority of children with microhaematuria (98.7%) and proteinuria (98.6%) at baseline were 
cured at follow-up. Following a second dose, the ERR, overall and morbidity cure rates increased to 100%. At one 
year post-treatment, 272 infected children (40.3%) were re-assessed; of these, 51 children (18.8%) were reinfected. 
Close proximity to bodies of water (odds ratio [OR] = 1.23, 95% confidence interval [CI]: 0.998–1.530; P = 0.05) and fishing 
(OR = 2.23, 95% CI: 0.828–6.040; P = 0.01) were significant factors that predisposed children to reinfection. Conclusion:
A moderate rate of reinfection was noted. Governmental and nongovernmental organisations in Nigeria should 
collaborate on mass treatment and health education campaigns to reduce the incidence of urinary schistosomiasis 
reinfections.
Keywords: Urinary Schistosomiasis; Praziquantel; Treatment Outcome; Follow-Up Study; Nigeria.
)اأعداد  الطفيلي  والعبء  البويل،  البلهار�شيا  داء  انت�شار  تقليل  برازيكوانتيل يف  لتقومي فعالية دواء  الدرا�شة  الهدف: هدفت هذه  امللخ�ص: 
لذلك  بالإ�شافة  درا�شتهم. ومتت  �شبقت  الذين  الدموية  البلهار�شية  امل�شابني بطفيل  الأطفال  املرا�شة يف عينات من  الطفيل(، ومعدلت 
درا�شة العوامل املوؤهبة لالإ�شابة جمددا بذات الطفيل بعد مرور عام على العالج بهذا الدواء. الطريقة: اأجريت درا�شة املتابعة امُل�شبقة هذه 
بني مار�ص 2014 وفرباير 2015م على 675 اأطفال م�شابني بطفيل البلهار�شية الدموية �شبقت درا�شتهم يف جمتمعي مورباي و�شورابي يف 
اأردي كول بولية ترابا بنيجرييا. ومت اإعطاء كل طفل م�شاب جرعة واحدة من دواء برازيكوانتيل قدرها 40 جمم/كجم، وبعد �شهر واحد 
بلغ متو�شط  النتائج:  العالج وبعده.  بدء  الأطفال قبل  بول  الطفيل يف  الأمر. ومت ح�شاب بي�ص  ا�شتلزم  اإن  لالأطفال  نف�ص اجلرعة  اأعطيت 
ن�شبة جناح العالج يف كل الأطفال %98.1. وبلغت معدلت النخفا�ص يف اأعداد البي�ص %100 و %96.5 عند الأطفال الذين كان لديهم 
عبء طفيلي منخف�ص واآخر مرتفع، على التوايل. و�ُشفي غالب الأطفال الذين كانت لديهم قبل العالج بيلة دموية )%98.7( وبيلة بروتينية 
)%98.6( بعد مرور عام على العالج. وبعد اإعطاء جرعة ثانية وجد اأن معدلت العائد القت�شادي، ومعدلت �شفاء املرا�شة الكلي قد زادت 
اإىل%100. وبعد عام على العالج متت اإعادة تقومي 272 طفال من امل�شابني بالطفيل )%40.3(، ووجد اأن 51 منهم )%18.8( قد اأ�شيبوا مرة 
اأخرى بالطفيل. وكان القرب ال�شديد من م�شادر املياه و �شيد الأ�شماك من العوامل املعنوية اإح�شائيا التي جعلت الأطفال عر�شة لالإ�شابة 
جمددا بالطفيل )ن�شبة الأرجحية = 1.23، %95 فا�شل الثقة: 1.530–0.998؛ P = 0.05( و �شيد الأ�شماك )ن�شبة الأرجحية =2.23، 95% 
فا�شل الثقة: 6.040–0.828؛ P = 0.01(. اخلال�صة: ينبغي اأن تقوم املنظمات احلكومية وغري احلكومية يف نيجرييا بالتعاون يف القيام 
بحمالت للعالج اجلماعي والتثقيف ال�شحي من اأجل تقليل حدوث عودة عدوى البلهار�شيا البولية.
الكلمات املفتاحية: البلهار�شيا البولية؛ برازيكوانتيل؛ نتائج العالج؛ درا�شة متابعة؛ نيجرييا. 
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Commonly known as bilharzia, schisto-somiasis is a water-related parasitic disease transmitted to humans transcutaneously by 
matured furcocercariae that multiply asexually within 
freshwater snails of the Planorbidae family.1 In sub-
Saharan Africa, Nigeria carries the highest burden 
of the disease, with an estimated 103.9 million people 
at risk of infection and 29 million individuals infected.2 
In Nigeria, the disease is predominantly caused by 
two species of schistosomes—Schistosoma haema-
tobium and S. mansoni—which overlap in most endemic 
areas, although S. intercalatum has also been reported.3,4 
For the most part, people living in rural areas of Nigeria 
are most often infected with S. haematobium.5,6 The 
disease is known to cause haematuria, proteinuria, 
leukocyturia, dysuria and painful urination; it has also 
been reported to have significant adverse effects on child 
development and to affect productivity in infected 
adults.1,7–9
In schistosomiasis-endemic areas, the World Health 
Organization (WHO) recommends the administration 
of a single dose of praziquantel to affected individuals 
during mass deworming campaigns.10 Previous studies 
have also shown that this drug remains the safest and 
most effective treatment for all forms of schistosom-
iasis.11,12 While poor cure rates with a single dose of 
praziquantel have been reported in S. mansoni-endemic 
areas, better cure and egg reduction rates (ERRs) have 
been reported in S. haematobium-endemic areas.12–15 
However, in spite of the dramatic increase in the avail- 
ability and distribution of praziquantel over the last 
decade, less than 40 million out of 260 million infected 
individuals worldwide in 2013 received treatment.15 
Moreover, in Nigeria, little has been done to reduce 
the prevalence and intensity of urinary schistosomiasis 
infections in endemic communities. Although a national 
schistosomiasis map was created to promote interven-
tions and strategies to combat the disease, only 4% of 
those in need of the drug have been treated so far.16,17 In 
Nigeria, previous studies have reported schistosomiasis 
to be endemic in Taraba State, with specific prevalence 
rates varying between communities.16,18 Despite this, 
to the best of the authors’ knowledge, there has been no 
mass distribution of praziquantel to date in this region.18 
The Murbai and Surbai villages of the Ardo Kola 
Local Government Area (LGA) of Taraba State are hyper- 
endemic areas for S. haematobium.18 Most residents are 
subsistence farmers who also engage in fishing and 
trading. The area has a tropical climate and a mixture of 
savannah vegetation.18 Ponds, streams and rivers traverse 
both communities, with the majority of inhabitants dep- 
endent on these bodies of water for their daily activ- 
ities. Previously, an epidemiological study was conducted 
among 1,153 children in the Murbai and Surbai comm- 
unities, of which 675 (58.5%) were found to be infected 
with S. haematobium; fishing, rice farming and dry season 
farming using irrigation were identified as significant 
risk factors for infection.18 However, only baseline prev-
alence and parasite burden was determined during the 
course of the initial study. Therefore, the current follow- 
up study aimed to assess the efficacy of a single dose of 
praziquantel in reducing prevalence, parasite burden 
and morbidity rates among the same sample of infected 
children. In addition, factors predisposing children to 
reinfection one year after treatment were evaluated.
Methods
This prospective follow-up study was conducted between 
March 2014 and February 2015 and included a previously 
reported sample of 675 children with urinary schist- 
osomiasis infections in the Murbai and Surbai comm-
unities.18 All infected children were treated with a 
single dose of 40 mg/kg of praziquantel administered 
by two qualified nurses according to WHO protocols.19 
The treated children were followed up for four weeks, 
after which they were re-examined to ascertain the 
presence of S. haematobium eggs in their urine. Those 
children who still excreted S. haematobium eggs at this 
time were given a second dose of praziquantel and 
followed up again for two more weeks before being re-
examined. After 12 months, all children who had been 
treated with either one or two doses of praziquantel 
were re-assessed for infection. Unfortunately, a number 
of the children’s families had left the villages during 
this time, frequently for agricultural purposes or so 
that the children could attend secondary schools in 
neighbouring villages. These children were therefore lost 
to further follow-up [Figure 1].
Advances in Knowledge 
- This follow-up study found that a single dose of praziquantel was highly effective in treating urinary schistosomiasis among a previously 
reported sample of infected children in Nigeria.
- However, proximity to bodies of water and participation in water-related activities such as fishing were significant factors predisposing 
children to reinfection one year after treatment.
Application to Patient Care
- The administration of a single dose of 40 mg/kg of praziquantel is recommended to cure children with urinary schistosomiasis of the 
disease, as well as related morbidities such as microhaematuria and proteinuria.
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Urine samples of 20 mL each were collected from 
the children at baseline and each subsequent follow-up 
appointment in labelled universal bottles. All samples 
were collected between 10 AM and 2 PM and were 
immediately tested for microhaematuria and proteinuria 
using reagent strips (Medi-Test Combi 9®, Machery-
Nagel GmbH Co., Düren, Germany), as per the manu-
facturer’s instructions. All tested urine samples were 
kept in an ice-packed cooler and transported to the lab- 
oratory within 30 minutes. The urine samples were filtered 
using a 10 mL syringe with a Swinnex® polypropylene 
filter holder of 13 mm in diameter and polycarbonate 
membrane filters of 12 μm porosity (Sterlitech Corp., 
Kent, Washington, USA). Positive samples were classified 
as having either a low (1–49 eggs/10 mL of urine) or high 
(>50 eggs/10 mL of urine) parasite burden. Cure rates 
and ERRs were calculated using the following formulae, 
where P is prevalence and MEC is the arithmetic mean 
egg count per 10 mL of urine:20
Data were entered into an Excel spreadsheet, Vers- 
ion 2010 (Microsoft Inc., Redmond, Washington, USA), 
before being exported for analysis to the Statistical 
Package for the Social Sciences (SPSS), Version 23 (IBM 
Corp., Armonk, New York, USA). Chi-squared and t- 
tests were used to compare the prevalence of infection 
and parasite burden according to age and gender 
and to compare the mean number of eggs between 
those with low and heavy parasite burdens. A logistic 
regression analysis using odds ratios (ORs) and 95% 
confidence intervals (CIs) was used to determine the 
relationship between reinfection and risk factors. The 
statistical level of significance was set at P ≤0.05.
Ethical permission to conduct this study was 
obtained from the Health Department of the Ardo Kola 
LGA (#HD/AIK/16/003). Thereafter, the Health Depart- 
ment communicated with the heads of the Murbai and 
Surbai communities to inform children and their parents 
of the study protocols. The parents or guardians of all 
children enrolled in the study provided informed con-
sent prior to their participation.
Results
This follow-up study included 675 previously reported 
children infected with S. haematobium prior to praziq- 
uantel treatment. As previously described, males were 
significantly more likely to be infected than females 
(71.2% versus 43.7%; χ2= 89.1; P <0.01).18 Children aged 
6–10 years and 11–15 years were also significantly 
more likely to be infected (78.7% and 73%, respect-
ively; χ2 = 360.9; P <0.01). A low parasite burden was 
significantly more frequent in comparison to a heavy 
parasite burden (62.5% versus 37.5%; χ2 = 97; P <0.01).18 
According to gender, females more frequently had a 
low parasite burden than males (70.1% versus 58.6%; 
χ2 = 96.9; P <0.01). Children aged 1–5 and 11–15 years 
old frequently had a low parasite burden (85.7% and 
55.7%, respectively).18
Table 1 presents the schistosomiasis parasite burden 
and morbidity rates of the children at baseline. The 
mean number of eggs was 31.1 ± 7.9 eggs/10 mL of 
urine among children with a low parasite burden and 
86.5 ± 12.1 eggs/10 mL of urine among those with a 
heavy parasite burden. In terms of morbidities, males 
had a significantly higher proportion of both microhaem- 
aturia (61.5% versus 42.9%; χ2 = 157.8; P <0.01) and 
proteinuria (49.1% versus 36.8%; χ2 = 107.9; P <0.01) 
than their female counterparts. Children aged 6–10 
and 11–15 years old had the highest proportion of 
both microhaematuria (61.7% and 48.3%, respectively; 
χ2 = 177.7; P <0.01) and proteinuria (44% and 50%, resp-





P before treatment – P after treatment
1 – MEC after treatment at baseline
P before treatment
MEC before treatment
Figure 1: Diagram of study design showing the number 
of infected children at baseline, follow-up and one year 
post-treatment among a sample of previously reported 
children with Schistosoma haematobium infections in 
Taraba State, Nigeria (N = 675).18
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Table 2 describes the schistosomiasis prevalence, 
parasite burden and morbidity rates of the children four 
weeks after the administration of a single dose of prazi- 
quantel. The overall cure rate was 98.1%, with only 13 
children (1.9%) requiring a second dose of praziquantel. 
Children aged 1–5 years old had a higher cure rate than 
older children (100% versus 98.6% and 96% for those 
aged 6–10 years and 11–15 years, respectively). In 
addition, female children had a higher cure rate than 
their male counterparts (99.6% versus 97.3%). At four 
weeks post-treatment, the ERR in children with low and 
heavy parasite burdens was 100% and 96.5%, respect-
ively. At this time, 5.1% of the children who had had a 
heavy parasite burden at baseline had relapsed, although 
Table 1: Schistosomiasis parasite burden and morbidities at baseline among Schistosoma haematobium-infected 
children in Taraba State, Nigeria (N = 675)*












Low 422 (62.5) 260 (58.6) 162 (70.1) <0.01 54 (85.7) 270 (61.9) 98 (55.7) <0.01
Mean eggs/10 mL 
of urine ± SD
31.1 ± 7.9 32.6 ± 4.2 29.7 ± 3.1 22.1 ± 7.3 36.3 ± 9.7 34.4 ± 5.6
High 253 (37.5) 184 (41.4) 69 (29.9) <0.01 9 (14.3) 166 (38.1) 78 (44.3) <0.01
Mean eggs/10 mL 
of urine ± SD
86.5 ± 12.1 88.3 ± 11.3 77.1 ± 9.4 75.3 ± 6.2 98.6 ± 8.7 84.4 ± 9.4
Morbidities
Microhaematuria 372 (55.1) 273 (61.5) 99 (42.9) <0.01 18 (28.6) 269 (61.7) 85 (48.3) <0.01
Proteinuria 303 (44.9) 218 (49.1) 85 (36.8) <0.01 23 (36.5) 192 (44) 88 (50) <0.01
SD = standard deviation.
*Some data previously reported in: Houmsou RS, Agere H, Wama BE, Bingbeng JB, Amuta EU, Kela SL. Urinary schistosomiasis among children in 
Murbai and Surbai communities of Ardo-Kola Local Government Area, Taraba State, Nigeria.18  †Parasite burden was classified as either low (1–49 
eggs/10 mL of urine) or high (>50 eggs/10 mL of urine).
Table 2: Schistosomiasis infections, parasite burden and morbidities at four weeks post-praziquantel treatment among 
Schistosoma haematobium-infected children in Taraba State, Nigeria (N = 675)











Infections 13 (1.9) 12 (2.7) 1 (0.4) <0.01 0 (0) 6 (1.4) 7 (4) <0.01
Overall cure 
rate, %
98.1 97.3 99.6 - 100 98.6 96 -
Parasite burden*
Low 13 (1.9)† 12 (2.7) 1 (0.4) <0.01 0 (0.0) 6 (1.4) 7 (3.9) <0.01
Mean eggs/10 
mL of urine ± SD
7.1 ± 1.1 7 ± 0.2 5 ± 1.9 - - 7.0 ± 1.4 4.1 ± 2.4 -
High 0 (0) 0 (0) 0 (0) - 0 (0) 0 (0) 0 (0) <0.01
Mean eggs/10 
mL of urine ± SD
- - - - - - - -
Morbidities
Microhaematuria 11 (1.6) 10 (2.3) 1 (0.4) <0.01 0 (0) 6 (1.4) 5 (2.8) <0.01
Cure rate, % 98.7 98 99.7 - - 98.7 97.5 -
Proteinuria 10 (1.5) 9 (2) 1 (0.4) <0.01 0 (0) 6 (1.4) 4 (2.3) <0.01
Cure rate, % 98.6 97.9 99.6 - - 98.5 97.8 -
SD = standard deviation.
*Parasite burden was classified as either low (1–49 eggs/10 mL of urine) or high (>50 eggs/10 mL of urine).  †All of the children who relapsed had initially 
had a high parasite burden at baseline but a low parasite burden four weeks post-treatment.
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their parasite burden at follow-up was low (mean: 
7.1 ± 1.1 eggs/10 mL of urine). In terms of morbidity, 
cure rates of microhaematuria and proteinuria four 
weeks post-treatment were 98.7% and 98.6%, respect-
ively. Among those children who had received a second 
dose of praziquantel, the ERR and overall and morbidity 
cure rates were 100% six weeks post-treatment.
Table 3 shows the prevalence of S. haematobium 
reinfections and related risk factors one year post-treat- 
ment among the 272 children (40.3%) available for follow- 
up. In total, 51 children (18.8%) were reinfected. However, 
reinfection rates did not vary significantly by gender 
(χ2 = 0.73; P = 0.72) or age (χ2 = 1.71; P = 0.13). However, 
close proximity (i.e. within <500 m) to a body of water 
(OR = 1.23, 95% CI: 0.998–1.530; P = 0.05) and fishing 
(OR = 2.23, 95% CI: 0.828–6.040; P = 0.01) were signif-
icant risk factors for reinfection.
Discussion
To the best of the authors’ knowledge, the current study 
represents the first longitudinal assessment of the efficacy 
of a single dose of praziquantel among a sample of 
previously reported S. haematobium-infected children 
in Taraba State.18 The results of the current study dem- 
onstrated the efficacy of praziquantel in reducing the 
prevalence, burden and morbidity of schistosomiasis 
infections in two communities with no prior record of 
mass drug administration. Moreover, observed cure 
rates at both four (98.1%) and six (100%) weeks post-
treatment indicated good absorption of praziquantel 
among infected children who had not previously been 
exposed to the drug.
Praziquantel remains the drug of choice for treating 
schistosomiasis, pending development of a more reliable 
single-dose cure.10 The findings of the present study 
corroborate those of another study from the southern 
Ivory Coast, which observed similarly high cure rates 
among infected children at 3–9 weeks post-treatment.20 
However, in contrast, previous research from Nigeria 
and Cameroon has indicated much lower cure rates at 
3–8 weeks post-treatment (49.4% and 39.8%, respect- 
ively).21,22 This variation in reported cure rates could be 
the result of several factors, including the frequency 
of the children’s exposure to infested waters, the rate 
of drug absorption and the extent of drug resistance 
among the studied populations. 
Although no significant gender or age differences 
were reported in schistosomiasis cure rates at four weeks 
post-treatment in the current study, females and 1–5- 
year-olds nevertheless had higher cure rates. This finding 
suggests that praziquantel may be more effective among 
younger children than older ones, likely due to increased 
exposure to cercariae-infested water among the latter 
group due to recreational activities or daily chores.18 This 
may similarly apply to male children; an earlier report 
observed that male children in Murbai and Surbai 
spent most of their time swimming and fishing in pools 
or lakes, as well as more frequently involving them-
selves in irrigation and rice farming activities.18 Lower 
cure rates among older children and males could also 
be due to the presence of schistosomula in the blood-
stream at the time of treatment, given that praziquantel 
has proven ineffective against immature Schistosoma 
parasites.23
In the present study, none of the children who 
required a second dose of praziquantel excreted S. haem- 
atobium eggs or showed any signs of morbidity at six 
weeks post-treatment, suggesting that a second dose of 
praziquantel may be necessary following poor response 
to the initial dose. A study conducted in the Niger 
Republic reported a similar ERR and cure rate after 
S. haematobium-infected children received a second dose 
Table 3: Schistosomiasis reinfection rates and related risk 
factors at one year post-praziquantel treatment among 
Schistosoma haematobium-infected children in Taraba 


























































OR = odds ratio; CI = confidence interval.
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of praziquantel three weeks post-treatment.24 However, 
the ERR and cure rate among children in the current 
study who received either a single or two doses of 
praziquantel was significantly higher than rates reported 
from Cameroon, wherein optimal results were only noted 
at nine weeks post-treatment, with doses of praziquantel 
administered at three-week intervals.22 Moreover, in the 
present study, most children with a low parasite burden 
were cured at follow-up, with only a few children with 
heavy parasite burdens at baseline relapsing at four 
weeks post-treatment. Similarly, previous research from 
Mozambique found that a single dose of praziquantel 
was more effective among children with a low parasite 
burden in comparison to those with a heavy parasite 
burden.25
In terms of schistosomiasis-related morbidity, the 
vast majority of children in the present study were cured 
of microhaematuria and proteinuria at four weeks post- 
treatment. This indicates that a single dose of praziquantel 
can potentially reverse the adverse effects of S. haemat- 
obium infections. In addition, none of the children 
requiring a second dose of praziquantel were found to 
suffer from these morbidities at six weeks post-treatment. 
Previous studies from Ethiopia and the Ivory Coast 
have reported low cure rates for microhaematuria and 
proteinuria at seven and eight weeks post-treatment, 
respectively.20,26 Most studies evaluating the efficacy of 
praziquantel have assessed morbidity markers of S. haem- 
atobium over several months and not within weeks. In 
Kenya, cure rates of 58% and 46% were observed at 
12 months post-treatment for microhaematuria and 
proteinuria, respectively.27 
Unfortunately, a moderate rate of schistosomiasis 
reinfection was noted among treated children one 
year post-treatment in the current study. This rate 
was comparatively higher than reported rates among 
treated children in Kenya and Sudan.27,28 This finding 
clearly demonstrates the challenges that rural comm-
unities such as Murbai and Surbai face with regards to 
the complete eradication of schistosomiasis. Unfort-
unately, the lack of piped water in these communities 
often compels the inhabitants to continue exposing 
themselves to cercariae-infested bodies of water—for 
instance, in order to carry out domestic chores or 
activities such as washing utensils and clothes, bathing, 
swimming and fishing—thereby re-infecting themselves. 
As previously reported, close proximity to bodies of 
water and fishing were identified as major factors that 
exposed children to infection.18 In the current follow-
up study, such factors remained significantly associated 
with reinfection rates one year post-treatment.
Prompt action is necessary so as to avoid a schist- 
osomiasis epidemic in Taraba State. To this end, a mass 
praziquantel campaign is recommended, in which all 
infected individuals are given at least two standard doses 
of 40 mg/kg of praziquantel at six-week intervals, in 
order to curtail the incidence of schistosomiasis reinf- 
ections in this region. Furthermore, the effects of praziq-
uantel treatment should be monitored in weeks rather 
than months. There is also an urgent need to address the 
problem of high reinfection rates through public health 
education initiatives to warn local inhabitants of risk 
factors associated with schistosomiasis reinfections. In 
addition, the provision of piped water as well as the 
installation of new or the re-activation of old boreholes 
or wells within these communities could help to reduce 
the inhabitants’ contact with cercariae-infested water, 
thereby reducing the incidence of new and recurrent 
schistosomiasis infections.
The present study is subject to certain limitations. 
First, an egg viability test was not performed after the 
initial treatment in order to determine whether the single 
dose of praziquantel had completely cured the infected 
children. Second, only 40.3% of the treated children 
were still residing within the studied villages one year 
post-treatment, thus limiting the total number of cases 
re-assessed.
Conclusion
Praziquantel was highly effective in curing schistosom-
iasis among a previously reported sample of S. haemat-
obium-infected children in Taraba State. At four weeks 
post-treatment, both the ERR and overall and morbidity 
cure rates were extremely high; these increased to 100% 
six weeks post-treatment following a second dose of 
praziquantel. However, there was a moderate rate of 
reinfection one year post-treatment. Proximity to bodies 
of water and fishing were significant risk factors for 
reinfection. The Nigerian Government and other agencies 
should initiate necessary strategies for treatment and 
public health education in the region. In particular, the 
provision of piped water is highly recommended in 
order to reduce the local inhabitants’ contact with 
cercariae-infested water.
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